• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-K filed by Perrigo Company plc

    6/10/24 4:23:04 PM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PRGO alert in real time by email
    8-K
    PERRIGO Co plc 00-0000000 false 0001585364 0001585364 2024-06-07 2024-06-07 0001585364 prgo:OrdinaryShares0001ParValueMember 2024-06-07 2024-06-07 0001585364 prgo:A39SeniorNoteDue2024Member 2024-06-07 2024-06-07 0001585364 prgo:M4.375NotesDue2026Member 2024-06-07 2024-06-07 0001585364 prgo:A4650SeniorNotesDueJune152030Member 2024-06-07 2024-06-07 0001585364 prgo:M5.300NotesDue2043Member 2024-06-07 2024-06-07 0001585364 prgo:M4.900NotesDue2044Member 2024-06-07 2024-06-07

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 OR 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported):

    June 7, 2024

     

     

    Perrigo Company plc

    (Exact name of registrant as specified in its charter)

     

     

    Commission File Number 001-36353

     

    Ireland     Not Applicable

    (State or other jurisdiction of

    incorporation or organization)

        (IRS Employer
    Identification No.)

    The Sharp Building, Hogan Place, Dublin 2, Ireland D02 TY74

    +353 1 7094000

    (Address, including zip code, and telephone number, including

    area code, of registrant’s principal executive offices)

    Not Applicable

    (Former name or former address, if changed since last report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities Registered pursuant to section 12(b) of the Act:

     

    Title of each class

     

    Trading
    Symbol(s)

     

    Name of each exchange

    on which registered

    Ordinary shares, €0.001 par value   PRGO   New York Stock Exchange
    3.900% Notes due 2024   PRGO24   New York Stock Exchange
    4.375% Notes due 2026   PRGO26   New York Stock Exchange
    4.650% Notes due 2030   PRGO30   New York Stock Exchange
    5.300% Notes due 2043   PRGO43   New York Stock Exchange
    4.900% Notes due 2044   PRGO44   New York Stock Exchange

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     


    Item 5.02.

    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

    On June 7, 2024, the Board of Directors of Perrigo Company plc (the “Company” or “Perrigo”) appointed Todd Penegor to serve as a member of the Company’s board of directors (the “Board”), to be effective June 21, 2024. Mr. Penegor will also serve on the Audit Committee of the Board.

    Mr. Penegor brings substantial experience as both a Chief Executive Officer and Chief Financial Officer of large companies. He most recently served as Chief Executive Officer for The Wendy’s Company (Nasdaq: WEN), from 2016 to 2024, where he also previously served as Chief Financial Officer from 2013 to 2015. Prior to this, Mr. Penegor worked at Kellogg Company, a global leader in food products, from 2000 to 2013 where he held several key leadership positions in finance and executive roles. Before joining Kellogg, Mr. Penegor worked for 12 years at Ford Motor Company in various positions, including strategy, mergers and acquisitions, the controller’s office and treasury.

    There are no arrangements or understandings between Mr. Penegor and any other person pursuant to which he was selected as a director of the Company. For his service on the Board, Mr. Penegor will be entitled to receive compensation provided to non-employee directors as approved by the Board and described in the Company’s proxy statement filed on March 22, 2024.


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

        (Registrant)
        PERRIGO COMPANY PLC
        By:  

    /s/ Eduardo Bezerra

    Dated: June 10, 2024       Eduardo Bezerra
          Chief Financial Officer
    Get the next $PRGO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PRGO

    DatePrice TargetRatingAnalyst
    11/6/2025$20.00Overweight → Neutral
    Analyst
    1/14/2025Buy → Hold
    Argus
    1/6/2025$34.00 → $27.00Overweight → Neutral
    Piper Sandler
    9/24/2024$50.00 → $30.00Hold
    Jefferies
    11/17/2023$37.00Overweight
    Piper Sandler
    3/7/2023$49.00Buy
    Canaccord Genuity
    9/14/2022$46.00Hold → Buy
    Argus
    9/6/2022$48.00 → $54.00Equal Weight → Overweight
    Wells Fargo
    More analyst ratings

    $PRGO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP and CSO Lennox Abigail exercised 3,185 units of Ordinary Shares at a strike of $14.64 and covered exercise/tax liability with 1,660 units of Ordinary Shares, increasing direct ownership by 122% to 2,780 units (SEC Form 4)

    4 - PERRIGO Co plc (0001585364) (Issuer)

    2/10/26 4:33:29 PM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Alford Bradley A

    4 - PERRIGO Co plc (0001585364) (Issuer)

    12/16/25 10:51:48 AM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Parker Geoffrey M.

    4 - PERRIGO Co plc (0001585364) (Issuer)

    12/16/25 10:44:39 AM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRGO
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Perrigo Company plc

    SCHEDULE 13G - PERRIGO Co plc (0001585364) (Subject)

    2/5/26 2:31:15 PM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Perrigo Company plc

    SCHEDULE 13G/A - PERRIGO Co plc (0001585364) (Subject)

    11/14/25 12:19:22 PM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Perrigo Company plc

    10-Q - PERRIGO Co plc (0001585364) (Filer)

    11/5/25 3:20:40 PM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRGO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Perrigo downgraded by Analyst with a new price target

    Analyst downgraded Perrigo from Overweight to Neutral and set a new price target of $20.00

    11/6/25 8:47:26 AM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Perrigo downgraded by Argus

    Argus downgraded Perrigo from Buy to Hold

    1/14/25 8:38:48 AM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Perrigo downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded Perrigo from Overweight to Neutral and set a new price target of $27.00 from $34.00 previously

    1/6/25 8:24:36 AM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRGO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Parker Geoffrey M. bought $106,350 worth of Ordinary Shares (7,500 units at $14.18) (SEC Form 4)

    4 - PERRIGO Co plc (0001585364) (Issuer)

    11/14/25 10:45:37 AM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP and CSO Lennox Abigail bought $28,125 worth of Ordinary Shares (1,255 units at $22.41) (SEC Form 4)

    4 - PERRIGO Co plc (0001585364) (Issuer)

    9/10/25 4:19:48 PM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, General Counsel & Sec. Atkinson Charles bought $23,200 worth of Ordinary Shares (1,000 units at $23.20) (SEC Form 4)

    4 - PERRIGO Co plc (0001585364) (Issuer)

    9/9/25 3:47:36 PM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRGO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    July 13, 2023 - FDA Approves First Nonprescription Daily Oral Contraceptive

    For Immediate Release: July 13, 2023 Today, the U.S. Food and Drug Administration approved Opill (norgestrel) tablet for nonprescription use to prevent pregnancy— the first daily oral contraceptive approved for use in the U.S. without a prescription. Approval of this progestin-only oral contraceptive pill provides an option for consumers to purchase oral contraceptive medicine without a prescription at drug stor

    7/13/23 8:32:15 AM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRGO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    CRH, Carvana and Comfort Systems USA Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

    NEW YORK, Dec. 5, 2025 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, December 22, to coincide with the quarterly rebalance. The changes ensure that each index is more representative of its market capitalization range. The companies being removed from the S&P SmallCap 600 are no longer representative of the small-cap market space.  Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector Dec 22, 2025  S&P 500 Addition CRH CRH Mat

    12/5/25 5:49:00 PM ET
    $ASIX
    $BAH
    $BWA
    Major Chemicals
    Industrials
    Professional Services
    Consumer Discretionary

    Perrigo to Attend Morgan Stanley Global Consumer & Retail Conference

    DUBLIN, Nov. 18, 2025 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading provider of consumer health products, today announced that President and CEO Patrick Lockwood-Taylor and CFO Eduardo Bezerra are scheduled to participate in one-on-one investor meetings at the Morgan Stanley Global Consumer & Retail Conference on Tuesday, December 2nd, 2025. About Perrigo   Perrigo Company plc is a leading pure-play consumer health company with over a century of experience in providing high-quality health and wellness solutions to consumers primarily in North America and Europe. A

    11/18/25 8:00:00 AM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Perrigo Reports Third Quarter 2025 Financial Results From Continuing Operations

    Amid Soft Market Consumption Trends, Achieved Q3 2025 Dollar, Unit and Volume Share(1) Gains in 5 of 7 Over-The-Counter ("OTC") Store Brand Categories and Dollar Share Gains in Key Brands Despite Marketplace Challenges, Delivered Meaningful YTD 2025 EPS Growth(2) with Gross and Operating Margin Expansion  Initiates Strategic Review of Infant Formula Business (Announced in Separate Press Release); Continues Strategic Review of Oral Care Business; On-Track to Close Previously Announced Sale of Dermacosmetics Business in Q1'26 Updates Full Year 2025 Outlook Due Primarily to Infant Formula Industry Dynamics and Soft OTC Market Consumption Trends DUBLIN, Nov. 5, 2025 /PRNewswire/ --

    11/5/25 6:35:00 AM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRGO
    Financials

    Live finance-specific insights

    View All

    Perrigo Reports Third Quarter 2025 Financial Results From Continuing Operations

    Amid Soft Market Consumption Trends, Achieved Q3 2025 Dollar, Unit and Volume Share(1) Gains in 5 of 7 Over-The-Counter ("OTC") Store Brand Categories and Dollar Share Gains in Key Brands Despite Marketplace Challenges, Delivered Meaningful YTD 2025 EPS Growth(2) with Gross and Operating Margin Expansion  Initiates Strategic Review of Infant Formula Business (Announced in Separate Press Release); Continues Strategic Review of Oral Care Business; On-Track to Close Previously Announced Sale of Dermacosmetics Business in Q1'26 Updates Full Year 2025 Outlook Due Primarily to Infant Formula Industry Dynamics and Soft OTC Market Consumption Trends DUBLIN, Nov. 5, 2025 /PRNewswire/ --

    11/5/25 6:35:00 AM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Perrigo to Conduct Strategic Review of its Infant Formula Business

    DUBLIN, Nov. 5, 2025 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO) ("Perrigo" or "the Company"), a leading provider of consumer health products, today announced that it is initiating a strategic review of its infant formula business. The review will assess a full range of alternatives. This review is aligned with Perrigo's 'Three-S' (Stabilize, Streamline, Strengthen) plan and reflects the Company's commitment to disciplined capital allocation and supporting improved return on invested capital and total shareholder return. It will focus on a combination of accelerating cash flows and reassessing the Company's previously announced investment in this business of $240 million, while optimizin

    11/5/25 6:30:00 AM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Perrigo Announces Quarterly Dividend

    DUBLIN, Oct. 29, 2025 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading global provider of consumer health products, today announced that its Board of Directors declared a quarterly dividend of $0.290 per share, payable on December 16, 2025, to shareholders of record on November 28, 2025. About Perrigo Perrigo Company plc is a leading pure-play consumer health company with over a century of experience in providing high-quality health and wellness solutions to consumers primarily in North America and Europe. As a pioneer in the over-the-counter (OTC) self-care market,

    10/29/25 11:57:00 AM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRGO
    Leadership Updates

    Live Leadership Updates

    View All

    CRH, Carvana and Comfort Systems USA Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

    NEW YORK, Dec. 5, 2025 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, December 22, to coincide with the quarterly rebalance. The changes ensure that each index is more representative of its market capitalization range. The companies being removed from the S&P SmallCap 600 are no longer representative of the small-cap market space.  Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector Dec 22, 2025  S&P 500 Addition CRH CRH Mat

    12/5/25 5:49:00 PM ET
    $ASIX
    $BAH
    $BWA
    Major Chemicals
    Industrials
    Professional Services
    Consumer Discretionary

    Perrigo Announces Global Operations and Supply Chain Leadership Transition

    Ron Janish, EVP Global Operations and Supply Chain, to Retire Industry Veteran, Matt Winterman, Appointed EVP Product Supply, Operations Strategy & Transformation Officer DUBLIN, June 4, 2025 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading global provider of Consumer Self-Care Products, today announced the appointment of Matt Winterman as Executive Vice President, Product Supply, Operations Strategy and Transformation Officer, effective June 23, 2025. Mr. Winterman succeeds Ron Janish, who will retire from the Company on September 30, 2025, following a distinguished career at Perrigo spanning more than two decades. Both executives will closely work together to ensure a smooth tran

    6/4/25 8:30:00 AM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Perrigo Expands its Scientific Office; Appoints Abbie Lennox as Executive Vice President and Chief Scientific Officer

    Expanded Scientific Office Unifies Scientific-Focused Teams, Facilitating Seamless Collaboration Across Product Portfolio Lennox Most Recently Led Regulatory, Medical Affairs, Safety and Quality Teams, Plus Drove Product Innovation, at Bayer Consumer Health Previous Chief Scientific Officer, Alison Ives, to Lead Newly Formed Disruptive Growth Team DUBLIN, Jan. 6, 2025 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading global provider of Consumer Self-Care Products, today announced the expansion of its Chief Scientific Office by uniting and integrating all global quality, pharmacovigilance, patient safety, regulatory affairs and innovation teams, enhancing organizational agility and s

    1/6/25 8:00:00 AM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRGO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Perrigo Company plc

    SC 13G - PERRIGO Co plc (0001585364) (Subject)

    10/31/24 11:55:03 AM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Perrigo Company plc

    SC 13G - PERRIGO Co plc (0001585364) (Subject)

    2/13/24 1:05:29 PM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Perrigo Company plc (Amendment)

    SC 13G/A - PERRIGO Co plc (0001585364) (Subject)

    1/24/24 2:27:16 PM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care